203 related articles for article (PubMed ID: 29228650)
1. Ultrasensitive plasma ctDNA
Chen I; Raymond VM; Geis JA; Collisson EA; Jensen BV; Hermann KL; Erlander MG; Tempero M; Johansen JS
Oncotarget; 2017 Nov; 8(58):97769-97786. PubMed ID: 29228650
[TBL] [Abstract][Full Text] [Related]
2. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
4. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.
Guan S; Deng G; Sun J; Han Q; Lv Y; Xue T; Ding L; Yang T; Qian N; Dai G
Front Oncol; 2022; 12():926260. PubMed ID: 36081557
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
7.
Wang ZY; Ding XQ; Zhu H; Wang RX; Pan XR; Tong JH
Front Oncol; 2019; 9():1295. PubMed ID: 31850201
[No Abstract] [Full Text] [Related]
8. Prospective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.
Shah D; Wells A; Cox M; Dawravoo K; Abad J; D'Souza A; Suh G; Bayer R; Chaudhry S; Zhang Q; Cristofanilli M; Bentrem D; Chawla A
Ann Surg; 2024 Jan; ():. PubMed ID: 38258582
[TBL] [Abstract][Full Text] [Related]
9. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
Nitschke C; Markmann B; Walter P; Badbaran A; Tölle M; Kropidlowski J; Belloum Y; Goetz MR; Bardenhagen J; Stern L; Tintelnot J; Schönlein M; Sinn M; van der Leest P; Simon R; Heumann A; Izbicki JR; Pantel K; Wikman H; Uzunoglu FG
Clin Chem; 2023 Mar; 69(3):295-307. PubMed ID: 36644936
[TBL] [Abstract][Full Text] [Related]
10. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
Sci Rep; 2021 Oct; 11(1):20797. PubMed ID: 34675229
[TBL] [Abstract][Full Text] [Related]
11. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
[TBL] [Abstract][Full Text] [Related]
14. Performance evaluation of a CRISPR Cas9-based selective exponential amplification assay for the detection of KRAS mutations in plasma of patients with advanced pancreatic cancer.
Shen Y; Zhang X; Zhang L; Zhang Z; Lyu B; Lai Q; Li Q; Zhang Y; Ying J; Song J
J Clin Pathol; 2023 Sep; ():. PubMed ID: 37679033
[TBL] [Abstract][Full Text] [Related]
15. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.
Edland KH; Tjensvoll K; Oltedal S; Dalen I; Lapin M; Garresori H; Glenjen N; Gilje B; Nordgård O
Mol Oncol; 2023 Sep; 17(9):1857-1870. PubMed ID: 37341038
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
[TBL] [Abstract][Full Text] [Related]
18. Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer.
Yin JX; Hu WW; Gu H; Fang JM
J Cancer; 2021; 12(4):1258-1269. PubMed ID: 33442424
[No Abstract] [Full Text] [Related]
19. Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer.
Berger AW; Schwerdel D; Ettrich TJ; Hann A; Schmidt SA; Kleger A; Marienfeld R; Seufferlein T
Oncotarget; 2018 Jan; 9(2):2076-2085. PubMed ID: 29416754
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer.
Jiang J; Ye S; Xu Y; Chang L; Hu X; Ru G; Guo Y; Yi X; Yang L; Huang D
Front Oncol; 2020; 10():1220. PubMed ID: 32850360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
